SUNNYVALE, Calif., Jan. 19, 2017 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that its CyberKnife®
and TomoTherapy® Systems continue to set the bar for excellence in
customer satisfaction. The Accuray systems received the highest
composite overall user satisfaction rating among radiation
treatment delivery systems in the U.S., according to the Q4 2016 MD
Buyline Market Intelligence Briefing™. The most recent ratings
trend also shows Accuray has achieved the highest composite ratings
among industry peers for 11 of the past 12 quarters.
According to MD Buyline, the company achieved the highest scores
in the majority of categories measured including system
performance, system reliability, applications training, service
response time and service repair quality. CyberKnife and
TomoTherapy System users continue to "praise the high level of
reliability afforded by Accuray systems." In addition, CyberKnife
System users "highly recommend" the InCise™ Multileaf Collimator
mentioning "it makes the treatment time much more efficient."
Customer feedback also demonstrates Accuray systems are delivering
on radiation therapy department expectations. The system
performance ratings have exceeded the industry average for 14
consecutive quarters.
"Our goal is to provide customers with the resources they need
to confidently deliver best-in-class radiation treatments for their
cancer patients now and in the years to come. Accuray has expanded
customer education and training opportunities, and improved service
support, as part of our long-term commitment to delivering on this
objective," said Joshua H. Levine,
president and CEO of Accuray. "The Q4 MD Buyline results reinforce
the company's focus and our team's commitment to excellence in
meeting customers' needs."
For more information on the CyberKnife and TomoTherapy Systems
visit www.accuray.com.
MD Buyline, an independent market intelligence organization for
the healthcare industry, measures linear accelerator user
satisfaction based on evaluations by more than 3,300 hospitals in
its member network that use the product every day. Respondents rate
how satisfied they are with products from Accuray, Elekta and
Varian, using key metrics listed above along with installation and
implementation, applications training, and service repair quality.
(MD Buyline User Satisfaction Ratings, MD Buyline Market
Intelligence Briefing™ Q4 2016) © 2016 MD Buyline, All Rights
Reserved. Used with Permission January 4,
2017.
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality,
high-dose distributions to be confidently delivered to the patient
with extreme accuracy over a minimum number of treatments, reducing
side effects and preserving patients' quality of life. The
CyberKnife® System is the only robotic full-body radiosurgery
system available today. The TomoTherapy® H™ Series efficiently
enables physicians to customize treatment plans for the entire
range of radiation therapy patients and disease types. Its
innovative design enables treatment plans to be delivered with
integrated, daily CT image guidance, enhancing accuracy and
delivering highly precise, intensity-modulated radiation for
optimal sparing of healthy tissue and critical structures.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's report on Form 10-Q, filed on
November 1, 2016, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media
Contacts:
Beth
Kaplan
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
Sherry Feldberg
MSLGROUP
+1 (781) 684-6223
accuray@mslgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-continues-to-set-the-industry-standard-for-customer-satisfaction-300393203.html
SOURCE Accuray Incorporated